Learn More
inhibitors has not been possible, perhaps for a combination of reasons, including challenges in function-based screening assays and the intrinsic refractoriness of aquaporins to drug discovery (termed non-druggability). One area of recent progress is in AQP4-based therapeutics for neuromyelitis optica. The idea is to block the binding of pathogenic(More)
  • 1